Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.80 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.80 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylmorphine SCHEMBL14516212 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL18770594 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL15757784 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL14611951 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL24971 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL15653227 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL16922138 | 1.00 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL220710 | 0.99 | OPRD1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL29845657 | 0.98 | OPRM1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL17747970 | 0.98 | OPRM1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848351-B1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2025-01-15 | — | — | EP | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3064199-B1 | ABUSE-DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | BUZZZ PHARMACEUTICALS LTD (IE) | 2023-12-20 | — | — | EP | claimed |
| EP-3405179-B1 | CONTROL OF THE RELEASE OF WATER FROM A SOLID COMPOSITION CONTAINING WATER | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2023-08-09 | — | — | EP | claimed |
| EP-3313407-B1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2023-07-19 | — | — | EP | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-4565218-A1 | BIOSYNTHESIS OF SUBSTITUTED COMPOUNDS AND CANNABINOIDS | Invizyne Technologies, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240076699-A1 | BIOSYNTHESIS OF SUBSTITUTED COMPOUNDS AND CANNABINOIDS | INVIZYNE TECHNOLOGIES, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| WO-2024030866-A1 | BIOSYNTHESIS OF SUBSTITUTED COMPOUNDS AND CANNABINOIDS | INVIZYNE TECHNOLOGIES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023205619-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4228597-A1 | MODIFIED RELEASE SOFTGEL CAPSULES | R.P. Scherer Technologies, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3405179-B1 | CONTROL OF THE RELEASE OF WATER FROM A SOLID COMPOSITION CONTAINING WATER | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2023-08-09 | — | — | EP | disclosed |
| CN-115666653-A | Antibody-drug conjugates | 斯皮雷亚有限公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-1765303-B2 | ORAL TABLET SAFEGUARDED AGAINST ABUSE | GRUENENTHAL GMBH (DE) | 2022-11-23 | — | — | EP | disclosed |
| EP-3995151-A1 | LIPID COMPOSITION FOR ENCAPSULATING AN ACTIVE SUBSTANCE AND ALLOWING CONTROL OF THE SPEED OF RELEASE OF SAID ACTIVE SUBSTANCE | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022082222-A1 | MODIFIED RELEASE SOFTGEL CAPSULES | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-04-21 | — | — | WO | disclosed |